)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Actinogen Medical
Actinogen Medical (ACW) investor relations material
Actinogen Medical Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary18 Oct, 2026
Executive summary
XanaMIA pivotal Phase 2b/3 Alzheimer’s trial completed its last patient visit in late September; topline results remain on track for November 2026.
September-quarter cash was $15.9m; including expected net R&D tax rebate proceeds of ~ $6m, pro forma cash is ~ $21.9m, with runway to late CY2027 or into CY2028 if new trials are substantially partnership-funded.
Financial highlights
Net operating cash outflow was $6.206m for the September quarter; R&D payments were $4.332m and administration and corporate costs were $1.641m.
Cash and cash equivalents ended the quarter at $15.865m, down from $16.735m at the start of the period.
Net financing cash inflow was $5.336m, including $4.566m from option exercises and $987k from equity issues, less $217k in transaction costs.
Outlook and guidance
Topline XanaMIA results are expected in November 2026; preparations are underway for regulatory engagement and a potential final pivotal AD trial if results are positive.
Cash runway is forecast to extend to late CY2027 or into CY2028, assuming new trials are substantially funded through partnerships; trial-related cash burn is expected to abate as final invoices are settled.
Up to $22.5m may be received from listed option exercises, with expiry dates in May and September 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Actinogen Medical
- Pivotal Alzheimer's trial results due November 2026; strong R&D focus and cash runway to mid-2027.ACW
H2 2026 - Xanamem's pivotal trial targets unmet Alzheimer's needs, with topline results due Nov 2026.ACWStatus update
- Strong clinical progress and capital raise extend funding past key Alzheimer's trial results.ACWQ3 2026 TU
- Pivotal Alzheimer's trial surpasses key milestones; funding secured through late 2026.ACWH2 2025
- Strong clinical progress and capital raises position the company for late-stage trials into 2025.ACWH2 2024
- Positive interim trial results and FDA alignment drive clinical and financial momentum.ACWH1 2026
- Interim trial success and AUD 12m raise support pivotal Alzheimer's results in late 2026.ACWInvestor update
- Pivotal Alzheimer's trial on track, with strong safety, efficacy, and major milestones ahead.ACWCorporate Presentation
- Pivotal Alzheimer's trial fully enrolled; interim analysis in January, final results next November.ACWStatus Update
Next Actinogen Medical earnings date
AGM 202629 Nov, 2026
Actinogen Medical
Next Actinogen Medical earnings date
AGM 202629 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Actinogen Medical Limited is a biotechnology company focused on the development of treatments for cognitive impairment and neurodegenerative diseases. The company’s primary research centers on therapies that target neurological pathways involved in conditions such as Alzheimer's disease and other forms of cognitive decline. Actinogen Medical leverages its proprietary drug development platform to create innovative solutions aimed at improving brain health and cognitive function. Actinogen Medical Limited is headquartered in Sydney, Australia, and its shares are listed on the ASX.